Home » Stocks » InflaRx N.V.

InflaRx N.V. (IFRX)

Stock Price: $4.66 USD -0.06 (-1.27%)
Updated Oct 23, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 121.65M
Revenue (ttm) n/a
Net Income (ttm) -53.25M
Shares Out 26.11M
EPS (ttm) -1.39
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 23, 2020
Last Price $4.66
Previous Close $4.72
Change ($) -0.06
Change (%) -1.27%
Day's Open 4.70
Day's Range 4.54 - 4.73
Day's Volume 86,219
52-Week Range 2.25 - 9.70

More Stats

Market Cap 121.65M
Enterprise Value 7.01M
Earnings Date (est) Nov 18, 2020
Ex-Dividend Date n/a
Shares Outstanding 26.11M
Float 19.44M
EPS (basic) -2.05
EPS (diluted) -1.39
FCF / Share -1.68
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 465,248
Short Ratio 0.85
Short % of Float 2.39%
Beta 0.46
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 1.15
Revenue n/a
Operating Income -57.08M
Net Income -53.25M
Free Cash Flow -43.80M
Net Cash 114.64M
Net Cash / Share 4.39
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -24.60%
ROE -41.81%
ROIC -59.20%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (9)

Buy 2
Overweight 1
Hold 4
Underweight 0
Sell 2

Analyst Consensus: Overweight

Price Target

(103.86% upside)
Current: $4.66
Target: 9.50
*Average 12-month price target from 7 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Operating Income-57.08-37.82-19.55-7.12-3.78
Net Income-53.25-29.81-24.24-8.94-4.92
Shares Outstanding26.0025.109.412.36-
Earnings Per Share-2.05-1.19-2.58-3.80-2.10
Operating Cash Flow-43.20-21.55-12.15-4.99-3.31
Capital Expenditures-0.59-0.81-0.15-0.05-0.01
Free Cash Flow-43.80-22.36-12.30-5.05-3.32
Cash & Equivalents11515712329.123.30
Total Debt0.85----
Net Cash / Debt11515712329.123.30
Book Value107151119-25.69-17.62
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name InflaRx N.V.
Country Germany
Employees 43
CEO Niels Christoph Riedemann

Stock Information

Ticker Symbol IFRX
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: IFRX
IPO Date November 8, 2017


InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in the Germany and United States. Its C5a is an inflammatory mediator that is involved in the enhancement of a variety of autoimmune and other inflammatory diseases. The company's lead product candidate is IFX-1, an intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase IIb clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; to treat ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and for the treatment of pyoderma gangrenosum, a chronic inflammatory skin disorder, as well as developing IFX-1 for the treatment of oncological diseases. It also develops IFX-2 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases. InflaRx N.V. has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.